Literature DB >> 36001111

[Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat].

E Intert1, M Krause2, F Hennersdorf2, K Knop3, T Rosenkranz3.   

Abstract

A 53-year-old man presented with rhabdomyolysis and acute kidney injury. The symptoms were presumably caused by a drug-drug interaction between an antiretroviral drug combination and atorvastatin. As a booster, cobicistat can also increase the toxicity of statins via inhibition of the enzyme cytochrome p450 3A4 (CYP3A4). After stopping atorvastatin and after intravenous fluid therapy, the symptoms regressed completely.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Cytochrome P450 3A4 (CYP3A4); HIV; High active anti-retroviral therapy (HAART); Myopathy; Statins

Year:  2022        PMID： 36001111     DOI： 10.1007/s00108-022-01377-x

Source DB:  PubMed          Journal:  Inn Med (Heidelb)        ISSN： 2731-7080


  7 in total

Review 1.  Statin-Associated Autoimmune Myopathy.

Authors:  Andrew L Mammen
Journal:  N Engl J Med       Date:  2016-02-18       Impact factor: 91.245

2.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

3.  Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis.

Authors:  Ahad Eshraghian; Amir A'lam Kamyab
Journal:  Intern Med       Date:  2013-04-01       Impact factor: 1.271

4.  Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.

Authors:  Judith A Aberg; Craig A Sponseller; Douglas J Ward; Vladimir A Kryzhanovski; Stuart E Campbell; Melanie A Thompson
Journal:  Lancet HIV       Date:  2017-04-13       Impact factor: 12.767

5.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

6.  N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.

Authors:  Frances A Wood; James P Howard; Judith A Finegold; Alexandra N Nowbar; David M Thompson; Ahran D Arnold; Christopher A Rajkumar; Susan Connolly; Jaimini Cegla; Chris Stride; Peter Sever; Christine Norton; Simon A M Thom; Matthew J Shun-Shin; Darrel P Francis
Journal:  N Engl J Med       Date:  2020-11-15       Impact factor: 91.245

7.  Cobicistat: A case of mislabelled drug-drug interaction risk?

Authors:  David M Burger; Alexandra Calmy; Catia Marzolini
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.